27

1 Running title: Olfactory bulb volumetry after COVID-19 2 3 ORIGINAL CONTRIBUTION 4 Reduced Olfactory Bulb Volume Accompanies Olfactory Dysfunction 5 After Mild SARS-CoV-2 Infection 6 7 Marvin Petersen, MD<sup>1#</sup>; Benjamin Becker, MD<sup>2#</sup>; Maximilian Schell<sup>1</sup>, Carola Mayer<sup>1</sup>, 8 Felix L. Nägele<sup>1</sup>, Elina Petersen, MSc<sup>3,4</sup>; Raphael Twerenbold, MD<sup>3,4,5,6</sup>; Götz 9 Thomalla, MD<sup>1</sup>; Bastian Cheng, MD<sup>1</sup>; Christian Betz, MD<sup>2</sup>, Anna S. Hoffmann, MD<sup>2</sup> 10 11 <sup>1</sup> Department of Neurology, University Medical Center Hamburg-Eppendorf, 12 13 Hamburg, Germany 14 <sup>2</sup> Department of Otorhinolaryngology and Head and Neck Surgery, University Medical 15 Center Hamburg-Eppendorf, Hamburg, Germany <sup>3</sup> Population Health Research Department, University Heart and Vascular Center, 16 Hamburg, Germany 17 18 <sup>4</sup> Department of Cardiology, University Heart and Vascular Center, Hamburg, 19 Germany 20 <sup>5</sup> German Center for Cardiovascular Research (DZHK), partner site 21 Hamburg/Kiel/Luebeck, Hamburg, Germany 22 <sup>6</sup> University Center of Cardiovascular Science, University Heart and Vascular Center, 23 Hamburg, Germany 24 # These authors contributed equally 25 26

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

**SUMMARY Background**: Despite its high prevalence, the determinants of smelling impairment in COVID-19 remain not fully understood. In this work, we aimed to examine the association between olfactory bulb volume and the clinical trajectory of COVID-19related smelling impairment in a large-scale magnetic resonance imaging (MRI) analysis. Methodology/Principal: Data of non-vaccinated COVID-19 convalescents recruited within the framework of the Hamburg City Health Study COVID Program between March and December 2020 were analyzed. On average 8 months after recruitment, participants underwent MRI and neuropsychological testing as well as a structured questionnaire for olfactory function. Between March and April 2022 olfactory function was assessed at an additional timepoint including quantitative olfactometric testing with Sniffin' Sticks. **Results**: This study included 233 individuals recovered from mainly mild to moderate SARS-CoV-2 infections. Longitudinal assessment demonstrated a declining prevalence of olfactory dysfunction from 67.1% at acute infection, 21.0% at baseline examination and 17.5% at follow-up. Participants with post-acute olfactory dysfunction had a significantly lower olfactory bulb volume at scan-time than normally smelling individuals. Olfactory bulb volume predicted olfactometric scores at follow-up. Performance in neuropsychological testing was not significantly associated with the olfactory bulb volume. **Conclusions**: Our work demonstrates an association of long-term smelling dysfunction and olfactory bulb integrity in a sample of individuals recovered from mainly mild to moderate COVID-19. Collectively, our results highlight olfactory bulb volume as a surrogate marker that may inform diagnosis and guide rehabilitation strategies in COVID-19. Key words: COVID-19, MRI, Olfactory bulb, Olfactory dysfunction, SARS-CoV-2

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

**INTRODUCTION** The coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected societies worldwide. Olfactory dysfunction is among the most common symptoms in COVID-19 with a reported prevalence of up to 85%. (1-8) COVID-19 features olfactory dysfunction in varying degrees – e.g., anosmia, hyposmia or parosmia – which occur often before the onset of respiratory symptoms. (3) Compared to other COVID-19-related symptoms like cough, fever or fatigue, olfactory dysfunction proved to be more predictive of SARS-CoV-2 infection. (9,10) Despite its relevance, the understanding of the pathophysiology of SARS-CoV-2-related olfactory dysfunction is still incomplete. There is ongoing research in the mechanisms of COVID-19-related olfactory dysfunction. Commonly, anosmia in the absence of rhinorrhea or nasal congestion is described as an early symptom which suggests other causal mechanisms than a common cold with conductive deficits causing olfactory dysfunction. (3,4,11,12) SARS-CoV-2 might affect the olfactory system at different breakpoints of its trajectory ranging from disruption of sustentacular cells and olfactory sensory neurons situated in the olfactory mucosa to functional disarray of the olfactory cortex. (13,14) Yet, there is only vague understanding of how these aspects relate to clinical outcomes. Magnetic resonance imaging (MRI) provides a promising avenue to investigate the pathomechanistic substrates of olfactory dysfunction in SARS-CoV-2 infection in vivo. Previous MRI studies put emphasis on the integrity of the olfactory bulb (OB) as a structural correlate of olfactory function in general. (15-17) Volume reduction of the OB accompanies olfactory loss in conditions like acute or chronic rhinosinusitis and head trauma. (18) Abnormalities in psychophysical olfactory testing are demonstrably associated with OB volume alterations in health and disease. (19-21) Furthermore, the duration and degree of olfactory loss is proportional to the OB volume. (22) So far, studies relating OB volumetry and olfactory function in COVID-19 rely on case reports and small sample sizes yielding heterogeneous results. (14,23-27) Therefore, further investigations are warranted. Based on previous evidence, we hypothesized that olfactory dysfunction in COVID-19

corresponds with interindividual volumetric differences of the OB. To address this

97

98

99

100

101102

103

104105

106

107

108109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

hypothesis, we quantified the OB volume based on structural MRI to see if there is a difference in the OB volume between the smell impaired and the normal individuals and performed a longitudinal assessment of olfactory function in a large sample of individuals recovered from mainly mild to moderate COVID-19. We also addressed if the OB volume is predictive for the long-term olfactory function. As affections of the olfactory system might precede COVID-19-related neuropathology, we additionally probed for a relationship of OB alterations and neuropsychological test score results in an exploratory analysis. With this work we aimed to further the understanding of the effects SARS-CoV-2 exerts on the olfactory system and deepen our insight in the longitudinal trajectory of subjective smelling impairment as well as the pathophysiology underlying the clinical sequelae of COVID-19.

## MATERIALS AND METHODS

## Study population and clinical examination

In this work we investigated data from participants of the Hamburg City Health Study (HCHS) Covid Program with available MRI data. A detailed description of the study design has been published separately. (28,29) Our reporting complies with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement guidelines. (30) In brief, citizens of the city of Hamburg, Germany, were considered for enrollment if they met two criteria: (1) a laboratory-confirmed positive polymerase chain reaction (PCR) test for SARS-CoV-2, which was obtained between 1<sup>st</sup> March and 31<sup>st</sup> December 2020 but at least 4 months prior to study enrollment; (2) age between 45 and 74 years at the time of inclusion. An invitation was issued upon identification via the clinical information system of the University Medical Center Hamburg-Eppendorf or a response to a public call for participation. Recruited participants underwent an extended study protocol of the Hamburg City Health Study (HCHS): besides the standard HCHS work up including MRI and assessment of cognitive function (Trail Making Test B, Word List Recall, Animal Naming Test, Mini Mental State Exam), depressive symptoms (PHQ-9) and quality of life (EQ-5D), participants were required to retrospectively report on disease severity and SARS-CoV-2-associated symptoms via a structured questionnaire. (31) A mild to moderate COVID-19 severity was defined as a symptomatic disease course not requiring intensive care unit treatment. The presented study was only conducted based on the post-SARS-CoV-2 cohort – i.e., the matched cohort of control subjects as described previously could not be leveraged as the required high-resolution T2-weighted MRI data was not available. (28,32) To assess the trajectory of olfactory function, participants were reinvited

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

between 15th March and 15th April 2022. For a timeline of this study refer to supplementary figure E1. Follow-up investigations comprised a structured questionnaire regarding olfactory function as well as olfactometric assessment via Sniffin' Sticks Screening 12 test by two trained otorhinolaryngologists (B.B., A.S.H.). (33,34) The test score ranges from 0 to 12 (0-6: anosmia, 7-10: hyposmia, 11-12: normosmia) and is based on normative information derived from more than 1200 patients assessed with Sniffin' Sticks Screening and olfactive evoked potentials. Eventually, information about self-reported olfactory dysfunction (based on a yes/noquestion) from structured questionnaires was available for three timepoints: (1) during the acute infection, (2) at the baseline investigation and (3) at follow-up. MRI and neuropsychological testing were only performed during baseline examination. **Ethics approval** Written informed consent was obtained from all participants. The study was approved by the local ethics committee of the Landesärztekammer Hamburg (State of Hamburg Chamber of Medical Practitioners, PV5131) and conducted complying with the Declaration of Helsinki. (35) MRI acquisition High-resolution 3D T2-weighted images were acquired at baseline on a 3T scanner (MAGNETOM<sup>TM</sup>Skyra, Siemens Healthineers, Erlangen, Germany) with the following sequence parameters: TR=3200 ms, TE=407 ms, 256 axial slices, ST=0.94 mm, and IPR=0.9×0.9mm. Olfactory bulb segmentation We performed OB segmentation on high-resolution T2-weighted images leveraging a novel fully-automated deep learning-based pipeline specifically designed for OB volumetry. (36) All resulting segmentations underwent visual quality assessment. Exemplary segmentation results are illustrated in *figure 1* as well as *supplementary* materials E2-5. The summed volume of both OBs was used for further analysis. Statistical analysis OB volume and olfactometry scores were compared between individuals with and

without self-reported olfactory dysfunction (yes/no) at different timepoints employing

164

165

166

167

168

169

170

171

172

173

174

175

176

177

186

194

analyses of covariance (ANCOVA). Multiple linear regression analysis was performed for assessing the linear relationship of olfactometry scores, as well as neuropsychiatric scores with OB volume. A further ANCOVA was performed to test whether the OB volume at baseline differed between individuals with sustained olfactory dysfunction at follow-up and those that recovered until then. The association between the time interval from positive PCR to examination was assessed via Spearman correlation. Age, sex and smoking behavior were included as covariates in ANCOVAs and linear models as they represent potential confounders. Statistical computations and plotting were performed in Python 3.9.7 harnessing matplotlib (v.3.5.1), numpy (v.1.22.3), pandas (v.1.4.2), pingouin (v.0.5.1) and seaborn (v.0.11.2).

### **RESULTS**

## Sample characteristics

- Data from 233 HCHS Covid Program participants was available for primary analysis.
- Nine subjects were excluded pre-analysis: 3 since they reported to have had olfactory
- dysfunction before their SARS-CoV-2 infection, 3 because of a missing OB and 3
- because of erroneous segmentations. Thus, data from n=224 participants were available
- for the final analysis. Sample characteristics are summarized in *table 1*. On average
- participants were 55.79 [95% confidence interval (CI95); 54.83, 56.73] years old,
- 184 44.2% were female and 5.4% were current smokers. 8.4% of participants were
- hospitalized due to COVID-19.

## Longitudinal trajectory of olfactory function

- The baseline examination happened on average 253 days after the positive PCR test
- prompting recruitment, the follow-up at 663 days. 143 participants were available at
- follow-up (81 study drop-outs). Of these, 67.1% (n=96) described olfactory dysfunction
- during the acute phase of infection, 21.0% (n=30) at the baseline examination and
- 191 17.5% (n=25) at follow-up (*figure 2a*). Assessment of olfactory dysfunction severity
- via the visual analogue scale resulted in a coherent trajectory: 7.62 [CI95; 7.06, 8.18]
- 193 (acute infection), 3.79 [3.12, 4.47] (baseline), 2.96 [2.07, 3.84] (follow-up).

## Olfactometry

204

205

216

217

223

195 To assess long term olfactory outcomes, olfactometry with the Sniffin' Sticks Screening 12 test was performed on participants at follow-up. Olfactometry scores at follow-up 196 197 were 10.18 [CI95, 9.89, 10.48]. Participants with self-reported olfactory dysfunction at 198 the acute infection did not differ from normally smelling participants regarding 199 olfactometry scores at follow-up (mean [CI95], 10.04 [9.65, 10.44] vs. 10.46 [10.08,10.84],  $eta_p^2$ =0.01, p=0.211; supplementary materials E6). Yet, participants 200 with olfactory dysfunction at baseline had lower olfactometric scores than normally 201 202 smelling individuals (mean [CI95], 8.67 [7.73, 9.60] vs. 10.58 [10.36,10.81],  $eta_n^2=0.19$ , p<0.005) and the same applied for participants impaired at follow-up (mean 203

[CI95], 8.40 [7.33, 9.47] vs. 10.56 [10.34, 10.78],  $eta_n^2 = 0.22$ , p < 0.005).

## Olfactory bulb volume and olfactory function

206 The mean OB volume was 45.53 [CI95, 43.84, 47.21] mm<sup>3</sup>. The ANCOVA yielded no 207 significant group difference in OB volume at acute infection between individuals with 208 and without olfactory dysfunction (mean [CI95], 45.85 [43.26, 48.43] vs. 45.21[40.83, 49.59],  $eta_p^2=0.00$ , p=0.837; figure 2b). Individuals with self-reported sustained 209 olfactory dysfunction at baseline and at follow-up had significantly lower OB volume 210 211 than normally smelling subjects at that time (mean [CI95], baseline: 40.76 [36.08, 212 45.44] vs. 46.74 [44.22, 49.26],  $eta_p^2=0.03$ , p=0.046; follow-up: 40.45 [35.51, 45.38] vs. 46.55 [44.07, 49.03],  $eta_p^2 = 0.03$ , p = 0.036). In participants with olfactory 213 dysfunction lower OB volume was accompanied by a shorter time-period between a 214 215 positive PCR for SARS-CoV-2, signifying the timepoint of acute SARS-CoV-2

### **Longitudinal prediction of olfactory function**

OB volume derived from MRI at baseline was significantly linearly associated with

infection, and the baseline examination ( $r_{sp}$ =0.161, p=0.016; figure 2c).

- olfactometry scoring at follow-up ( $r_{sp}$ =0.154, p=0.025; figure 2d). Participants with
- sustained olfactory dysfunction at follow-up had lower OB volume at baseline (mean
- [CI95], 40.64 [35.51, 45.77] vs. 47.58 [44.68, 50.48],  $eta_p^2 = 0.06$ , p = 0.018; figure 2e)
- than those that had recovered by the time of reassessment.

## Clinical analysis

- To further explore potential clinical implications of our findings, correlations of OB
- volume and neuropsychological cognitive test scores and psychiatric test scores were

- performed. To summarize, no significant associations of OB volume and scores of the
- 227 Trail Making Test B ( $r_{sp}$ =0.014, p=0.722), Animal Naming Test ( $r_{sp}$ =-0.090, p=0.069),
- Word List Recall Test ( $r_{sp}$ =-0.050, p=0.587), Mini Mental State Exam ( $r_{sp}$ =-0.025,
- 229 p=0.689), PHQ-9 ( $r_{sp}=0.098$ , p=0.404) and EQ-5D ( $r_{sp}=-0.009$ , p=0.306) were found.
- 230 Corresponding visualizations are displayed in *supplementary materials E7*.

## **DISCUSSION**

231

232

233

245

246

- We report on an association of OB volume and olfactory dysfunction in a large sample
- of mainly mildly to moderately affected COVID-19 convalescents. Longitudinal
- assessment demonstrated sustained olfactory dysfunction up to two years after acute
- 237 infection. Participants suffering from olfactory dysfunction beyond acute infection had
- a significantly lower OB volume at baseline than normally smelling individuals.
- 239 Moreover, OB volume was predictive for olfactometric performance in the Sniffin'
- 240 Sticks test 22 months after the acute infection as well as for the binary outcome of
- 241 recovery from olfactory dysfunction at follow-up. Neuropsychological test
- 242 performances were not significantly associated with OB volume. Taken together, our
- 243 findings suggest that lower volume of the OB may be a promising surrogate marker of
- smelling function in COVID-19 at post-acute disease stages.

### Longitudinal trajectory of olfactory dysfunction

- 247 Its frequency and the concomitant effects on quality of life render olfactory dysfunction
- 248 a burdensome symptom of COVID-19. Our 2-year longitudinal assessment of olfactory
- 249 function provided insights about time-dependent development of these symptoms. At
- acute infection, the proportion of participants reporting olfactory dysfunction was
- 251 67.1% which is coherent with previous study reports ranging from 30% to 85%. (1-4,6,7)
- 252 After the acute infection, the prevalence decreased to 21% at the baseline examination
- 253 (on average 253 days post infection) and 17.5% at follow-up (on average 664 days post
- infection; figure 2a). These numbers support previous literature finding high rates of
- long term olfactory dysfunction in COVID-19. (43–45) Of note, a recent meta-analysis
- 256 reports persistent olfactory dysfunction in less patients (11.6%; 95% confidence
- interval 5.2% to 23.9%). We attribute this difference to design differences with
- 258 respect to our work: the studies included in the meta-analysis also considered young

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

adults (>18 years) possibly exhibiting higher regenerative capacity as well as recent SARS-CoV-2 variants demonstrably affecting patient olfaction less severely than the wild type variant mainly prevalent at the pandemic onset. (47) Overall, these findings indicate that although most former COVID-19 patients completely recover, subjective olfactory dysfunction persisted in relevant proportion of individuals. To assess long term olfactory outcomes, olfactometry with the Sniffin' Sticks Screening 12 test was performed at follow-up. Participants suffering from olfactory dysfunction beyond the acute infection, plausibly showed significantly lower olfactometry scores than normally smelling or recovering subjects. Collectively, our results support previous evidence of sustained olfactory dysfunction in around 20% of patients underscoring the possible long lasting burden following a SARS-CoV-2 infection. (6,44) Long-term olfactory dysfunction is associated with lower olfactory bulb volume Olfactory dysfunction is demonstrably accompanied by lower OB volume in many otorhinolaryngological conditions like post-infectious olfactory disorder, head trauma as well as acute and chronic rhinosinusitis. (18) In line with this notion, our work showed a lower OB volume in individuals with sustained olfactory dysfunction after the acute SARS-CoV-2 infection indicating COVID-19-related OB atrophy (figure 2b). Thus, our results corroborate previous reports derived from case studies and small samples suggesting lower OB volume in SARS-CoV-2-induced olfactory dysfunction. (23-26) Previous reports demonstrated an inverse correlation between OB volume and the duration of symptoms in post-infectious olfactory disorder suggesting its predictive capacity. (22) To further investigate this, we related the OB volume with olfactometry scores which were acquired approximately 1 year after the MRI. Notably, the OB volume predicted olfactometry scores at follow-up (figure 2d). Yet, the observed correspondence was of a rather low degree, indicating that further determinants of longterm olfactory dysfunction should be considered. Possibly, MRI assessment closer to the acute infection would have resulted in the observation of stronger effects. Furthermore, OB volume was higher in participants in which the smelling sense fully recovered until follow-up compared to those with sustained olfactory dysfunction (figure 2e). Hence, the OB volume appears to be a predictor of recovery from olfactory dysfunction, i.e., potentially capturing the severity of damage SARS-CoV-2 exerts on

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

the olfactory system. Interestingly, individuals exhibited higher OB volume the longer the time interval between the positive PCR and the MRI was (*figure 2c*). This might indicate that an increasing OB volume may reflect recovery of olfactory function. However, longitudinal imaging assessment is warranted here. Taken together, these findings suggest that a lower OB volume indicates more severe disruption of the olfactory system and predict persistent olfactory dysfunction in COVID-19 patients.

## Pathomechanistic underpinnings of abnormal olfactory bulb volume

There are multiple potential mechanisms that might explain the observed link between olfactory dysfunction and OB dysintegrity. In the olfactory mucosa, olfactory sensory neurons (OSN) – sensing molecular signatures as odor information – as well as supporting epithelial cells (sustentacular cells) ensure proper sense of smell. Sustentacular cells express angiotensin-converting enzyme 2 (ACE-2) and appear to be a major infection target of the virus. (13,48) As they support OSN in a glial-like fashion, impairment of sustentacular cells is considered to contribute to COVID-19-related olfactory dysfunction. (49) How OSN are affected by SARS-CoV-2 is controversial. Discussed mechanisms are neurotropism, affection by an impaired support system and damage caused by the immune response to the virus. (13,49,50) Recent analyses failed to detect signs of neurotropism and neural invasion through SARS-CoV-2 challenging the notion of the olfactory system serving the virus as an entry point. (49,51,52) As the OB serves as a relay for projections from the OSN, volumetric reductions might occur as an effect of indirect OSN affection - e.g., via inflammation or microvasculopathy rather than direct damage from the virus leading to reduced tissue integrity. (52) Taking the link between OB integrity and long-term olfactory function into account, OB volume might serve as an indicator of severe structural disruption of the olfactory system which corresponds with unfavorable outcomes. Nonetheless, further longitudinal neuroimaging research is warranted to support this notion.

#### Olfactory bulb volume is not associated with neuropsychological test scores

By now, COVID-19 is recognized to cause post-acute neurological and psychiatric symptoms like executive dysfunction, fatigue, anxiety, depression and sleep impairment. (53–56) Coherent with these observations, a comprehensive MRI analysis on COVID-19 convalescents from the UK Biobank has shown widespread gray matter volume reductions in areas receiving projections from the olfactory cortex. (54) Its

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

evident exposition to deleterious SARS-CoV-2 effects renders the OB a candidate indicator of COVID-19-related neuropathology beyond the olfactory system. Thus, we tested whether the OB volume is associated with results of neuropsychological test scores. OB volume showed no significant association with tests of cognitive function (Trail Making Test B, Word List Recall, Animal Naming Test), depressive symptoms (Patient Health Questionnaire-9, PHQ-9) and quality of life (EQ-5D). Consequently, pathology of the olfactory system might be disjunct to non-olfaction-related neuropathology in SARS-CoV-2 infection. Nonetheless, our findings might be partially attributable to the overall mild to moderate disease course captured in our sample resulting in negative results. Further investigations of determinants of neurological and psychiatric sequelae of COVID-19 are necessary.

## **Strengths and limitations**

The strengths of this work lie in its considerable sample size; high quality imaging and phenotypical data; a modern fully-automated MRI-based segmentation of the OB enabling volumetry at scale; olfactory assessment at different time points post infection, including quantitative olfactory testing (at follow-up) providing longitudinal information for up to 2 years. Yet, this study has some limitations. First, MRI acquisition and olfactometry with Sniffin' sticks were performed only at one timepoint, which makes it difficult to completely address pre-infectious group differences. For instance, our results could partially be explained by individuals with lower OB volume being more susceptible to olfactory dysfunction caused by SARS-CoV-2 infection. Previous work hypothesizes that smaller OB volume and pre-existing reduced number of olfactory receptor neurons increased the patient's vulnerability to develop postinfectious olfactory loss. With less functional tissue existing in the first place, damage to existing sensory cells might lead to more pronounced olfactory dysfunction. (57) Here, evidence from future longitudinal studies is warranted. As more severely impaired individuals might be more motivated and thus more likely to participate in our study than the average population, our results could possibly be influenced by our recruitment strategy. Additionally, a more in-depth assessment of olfactory function based on odor thresholds was not conducted at follow-up because high dropout rates due to compliance issues were expected. Parosmia may serve as a potential confounding factor in the observed associations, thus necessitating cautious interpretation of our results. Unfortunately, information on parosmia was not available for this study. Lastly, the

different SARS-CoV-2 strains appear to differ in terms of olfactory dysfunction frequency and intensity. Our study lacks information about SARS-CoV-2 strains rendering it incapable to address inter-strain differences. However, the investigation started at an early stage of the pandemic most likely soothing the problem of different COVID-19 strains and vaccinations as confounders.

## Conclusion

In this work, we performed OB volumetry as a neuroimaging marker of olfactory dysfunction in patients recovered from mainly mild to moderate COVID-19. By revealing an alteration of the OB in participants with olfactory dysfunction, our results highlight the relevance of the olfactory system in the overall pathophysiology of the disease. However, a connection between OB volume and neuropsychological signs of COVID-19 could not be established. Collectively, these results demonstrate that the OB is a promising target for assessment of olfactory dysfunction in COVID-19.

## **ACKNOWLEDGEMENTS**

The authors wish to acknowledge all participants of the Hamburg City Health Study and cooperation partners, patrons and the Deanery from the University Medical Center Hamburg—Eppendorf for supporting the Hamburg City Health Study. Special thanks applies to the staff at the Epidemiological Study Center for conducting the study. The participating institutes and departments from the University Medical Center Hamburg-Eppendorf contribute all with individual and scaled budgets to the overall funding. The Hamburg City Health Study is also supported by Amgen, Astra Zeneca, Bayer, BASF, Deutsche Gesetzliche Unfallversicherung (DGUV), DIFE, the Innovative medicine initiative (IMI) under grant number No. 116074 and the Fondation Leducq under grant number 16 CVD 03., Novartis, Pfizer, Schiller, Siemens, Unilever and "Förderverein zur Förderung der HCHS e.V.". The publication has been approved by the Steering Board of the Hamburg City Health Study.

## **AUTHORSHIP CONTRIBUTION**

395 We describe contributions to the paper using the CRediT contributor role taxonomy. 396 Conceptualization: M.P., A.S.H.; Data Curation: M.P., B.B., M.S., C.M., F.N., A.S.H.; 397 Formal analysis: M.P.; Funding acquisition: G.T, B.C, C.B., A.S.H.; Investigation: 398 M.P., B.B., M.S., C.M., F.N., E.P., R.T., G.T., B.C., C.B., A.S.H.; Methodology: M.P.; 399 Software: M.P.; Supervision: C.B., A.S.H.; Visualization: M.P.; Writing—original 400 draft: M.P., B.B.; Writing—review & editing: M.P., B.B., M.S., C.M., F.N., E.P., R.T., 401 G.T., B.C., C.B., A.S.H. 402 Data access: M.P., B.B., and A.S.H. had full access to all the data in the study and take 403 responsibility for the integrity of the data and the accuracy of the data analysis. 404 405 **CONFLICT OF INTEREST** 406 GT has received fees as consultant or lecturer from Acandis, Alexion, Amarin, Bayer, 407 Boehringer Ingelheim, BristolMyersSquibb/Pfizer, Daichi Sankyo, Portola, and Stryker 408 409 outside the submitted work. The remaining authors declare no conflicts of interest. 410 411 **FUNDING** 412 413 This work was supported by grants from the German Research Foundation (Deutsche 414 Forschungsgemeinschaft, DFG), Schwerpunktprogramm (SPP) 204 – project number 454012190 – and Sonderforschungsbereich (SFB) 936 – project number 178316478 – 415 416 Project C2 (M.P., C.M., G.T., and B.C.). 417 418 **DATA AVAILABILITY** 419 420 Data will be made available on reasonable request from any qualified investigator after 421 evaluation of the request by the Steering Board of the HCHS. Analysis code and 422 documentation publicly (https://github.com/csiis available on GitHub 423 hamburg/CSIframe/blob/main/pipelines/obseg/obseg.sh, https://github.com/csi-424 https://github.com/csihamburg/CSIframe/wiki/Olfactory-bulb-segmentation and 425 hamburg/2022\_petersen\_ob\_postcovid). 426

#### REFERENCES

427

428

- 429 1. von Bartheld CS, Hagen MM, Butowt R. Prevalence of Chemosensory
- 430 Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis
- 431 Reveals Significant Ethnic Differences. ACS Chem Neurosci. 2020;11(19):2944–
- 432 61.
- 433 2. Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and
- 434 Assessment of an Olfactory Route to Brain Infection. Neuroscientist.
- 435 2021;27(6):582–603.
- 436 3. Cooper KW, Brann DH, Farruggia MC, et al. COVID-19 and the Chemical Senses:
- 437 Supporting Players Take Center Stage. Neuron. 2020;107(2):219–33.
- 438 4. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory
- dysfunctions as a clinical presentation of mild-to-moderate forms of the
- coronavirus disease (COVID-19): a multicenter European study. Eur Arch
- 441 Otorhinolaryngol. 2020;277(8):2251–61.
- 442 5. Eliezer M, Hautefort C, Hamel A-L, et al. Sudden and Complete Olfactory Loss of
- 443 Function as a Possible Symptom of COVID-19. JAMA Otolaryngology—Head &
- 444 Neck Surgery. 2020;146(7):674–5.
- 445 6. Lechien JR, Chiesa-Estomba CM, Beckers E, et al. Prevalence and 6-month
- recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19
- 447 patients. J Intern Med. 2021;290(2):451–61.
- 448 7. Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and
- Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-
- 450 analysis. Mayo Clinic Proceedings. 2020;95(8):1621–31.
- 451 8. Parma V, Ohla K, Veldhuizen MG, et al. More Than Smell-COVID-19 Is
- Associated With Severe Impairment of Smell, Taste, and Chemesthesis. Chem
- 453 Senses. 2020;45(7):609–22.
- 454 9. Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty
- 455 RL. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol.
- 456 2020;10(8):944–50.
- 457 10. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported
- 458 symptoms to predict potential COVID-19. Nat Med. 2020;26(7):1037–40.
- 459 11. Vaira LA, Deiana G, Fois AG, et al. Objective evaluation of anosmia and ageusia
- in COVID-19 patients: Single-center experience on 72 cases. Head Neck.
- 461 2020;42(6):1252–8.
- 462 12. Ahmed AK, Sayad R, Mahmoud IA, et al. "Anosmia" the mysterious collateral
- damage of COVID-19. J Neurovirol [Internet]. 2022 [cited 2022 Apr 19];
- 464 Available from: https://doi.org/10.1007/s13365-022-01060-9

- 465 13. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2
- invasion as a port of central nervous system entry in individuals with COVID-19.
- 467 Nat Neurosci. 2021;24(2):168–75.
- 468 14. Esposito F, Mario Cirillo, Rosa De Micco, et al. Olfactory loss and brain
- 469 connectivity after COVID -19. Human Brain Mapping. 2022;
- 470 15. Haehner A, Rodewald A, Gerber JC, Hummel T. Correlation of Olfactory
- 471 Function With Changes in the Volume of the Human Olfactory Bulb. Archives of
- 472 Otolaryngology–Head & Neck Surgery. 2008;134(6):621–4.
- 473 16. Lu R, Aziz NA, Reuter M, Stöcker T, Breteler MMB. Evaluation of the
- 474 Neuroanatomical Basis of Olfactory Dysfunction in the General Population.
- 475 JAMA Otolaryngology–Head & Neck Surgery. 2021;147(10):855–63.
- 476 17. Das S. Olfactory Bulb Volume—A Novel Preclinical Biomarker for Smell Loss and
- 477 Neurodegenerative Disease. JAMA Otolaryngology—Head & Neck Surgery.
- 478 2021;147(10):864-5.
- 479 18. Hummel T, Urbig A, Huart C, Duprez T, Rombaux P. Volume of olfactory bulb
- and depth of olfactory sulcus in 378 consecutive patients with olfactory loss. J
- 481 Neurol. 2015;262(4):1046–51.
- 482 19. Rombaux P, Mouraux A, Bertrand B, Nicolas G, Duprez T, Hummel T. Retronasal
- and orthonasal olfactory function in relation to olfactory bulb volume in
- patients with posttraumatic loss of smell. Laryngoscope. 2006;116(6):901–5.
- 485 20. Rombaux P, Weitz H, Mouraux A, et al. Olfactory function assessed with
- orthonasal and retronasal testing, olfactory bulb volume, and chemosensory
- 487 event-related potentials. Arch Otolaryngol Head Neck Surg.
- 488 2006;132(12):1346–51.
- 489 21. Rombaux P, Martinage S, Huart C, Collet S. Post-infectious olfactory loss: a
- 490 cohort study and update. B-ENT. 2009;5 Suppl 13:89–95.
- 491 22. Yao L, Yi X, Pinto JM, et al. Olfactory cortex and Olfactory bulb volume
- alterations in patients with post-infectious Olfactory loss. Brain Imaging Behav.
- 493 2018;12(5):1355–62.
- 494 23. Chiu A, Fischbein N, Wintermark M, Zaharchuk G, Yun PT, Zeineh M. COVID-19-
- induced anosmia associated with olfactory bulb atrophy. Neuroradiology.
- 496 2021;63(1):147-8.
- 497 24. Altunisik E, Baykan AH, Sahin S, Aydin E, Erturk SM. Quantitative Analysis of the
- 498 Olfactory System in COVID-19: An MR Imaging Study. AJNR Am J Neuroradiol.
- 499 2021;42(12):2207–14.

- 500 25. Güney B, Bacaksızlar Sarı F, Özdemir MY, Çullu N, Doğan E, Togan T. Changes in 501 olfactory bulbus volume and olfactory sulcus depth in the chronic period after 502 COVID-19 infection. Acta Otolaryngol. 2021;141(8):786-90. 503 Tsivgoulis G, Fragkou PC, Lachanis S, et al. Olfactory bulb and mucosa 504 abnormalities in persistent COVID-19-induced anosmia: a magnetic resonance 505 imaging study. Eur J Neurol. 2021;28(1):e6-8.
- 506 27. Frosolini A, Parrino D, Fabbris C, et al. Magnetic Resonance Imaging Confirmed 507 Olfactory Bulb Reduction in Long COVID-19: Literature Review and Case Series. 508 Brain Sciences. 2022;12(4):430.
- 509 Petersen EL, Goßling A, Adam G, et al. Multi-organ assessment in mainly non-510 hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health
- 511 Study COVID programme. European Heart Journal. 2022;ehab914.
- 512 29. Petersen M, Nägele FL, Mayer C, et al. Brain imaging and neuropsychological assessment of individuals recovered from a mild to moderate SARS-CoV-2 513 514 infection. Proceedings of the National Academy of Sciences.
- 515 2023;120(22):e2217232120.
- 516 30. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of 517 Observational Studies in Epidemiology (STROBE) statement: guidelines for 518 reporting observational studies. Lancet. 2007;370(9596):1453-7.
- 519 Petersen M, Nägele FL, Mayer C, et al. Brain network architecture constrains 520 age-related cortical thinning. NeuroImage. 2022;264:119721.
- 521 Petersen M, Nägele FL, Mayer C, et al. Brain imaging and neuropsychological 522 assessment of individuals recovered from mild to moderate SARS-CoV-2
- 523 infection [Internet]. medRxiv; 2022 [cited 2022 Dec 9]. p. 2022.07.08.22277420.
- 524 Available from:
- 525 https://www.medrxiv.org/content/10.1101/2022.07.08.22277420v1
- 526 33. Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory 527 dysfunction. Rhinol Suppl. 2017;54(26):1-30.
- 528 Hummel T, Welge-Lüssen A. Assessment of olfactory function. Adv 529 Otorhinolaryngol. 2006;63:84-98.
- 530 Petersen M, Frey BM, Schlemm E, et al. Network Localisation of White Matter 531 Damage in Cerebral Small Vessel Disease. Scientific Reports. 2020;10(1):9210.
- 36. Estrada S, Lu R, Diers K, et al. Automated olfactory bulb segmentation on high 532 533 resolutional T2-weighted MRI. NeuroImage. 2021;242:118464.
- 534 37. Fitzek M, Patel PK, Solomon PD, et al. Integrated age-related 535 immunohistological changes occur in human olfactory epithelium and olfactory 536

bulb. J Comp Neurol. 2022;530(12):2154-75.

537 38. Caswell TA, Droettboom M, Lee A, et al. matplotlib/matplotlib: REL: v3.5.2 538 [Internet]. Zenodo; 2022 [cited 2022 May 9]. Available from: 539 https://zenodo.org/record/6513224 540 Harris CR, Millman KJ, van der Walt SJ, et al. Array programming with NumPy. 541 Nature. 2020;585(7825):357-62. 542 Reback J, McKinney W, jbrockmendel, et al. pandas-dev/pandas: Pandas 1.0.3 543 [Internet]. Zenodo; 2020 [cited 2022 May 9]. Available from: 544 https://zenodo.org/record/3715232 545 41. Vallat R. Pingouin: statistics in Python. JOSS. 2018;3(31):1026. 546 42. Waskom ML. seaborn: statistical data visualization. Journal of Open Source 547 Software. 2021;6(60):3021. 548 43. Mendes Paranhos AC, Nazareth Dias ÁR, Machado da Silva LC, et al. 549 Sociodemographic Characteristics and Comorbidities of Patients With Long 550 COVID and Persistent Olfactory Dysfunction. JAMA Network Open. 551 2022;5(9):e2230637. 552 Boscolo-Rizzo P, Hummel T, Hopkins C, et al. High prevalence of long-term 553 olfactory, gustatory, and chemesthesis dysfunction in post-COVID-19 patients: a 554 matched case-control study with one-year follow-up using a comprehensive 555 psychophysical evaluation. Rhinology. 2021;59(6):517–27. 556 Lucidi D, Molinari G, Silvestri M, et al. Patient-reported olfactory recovery after 557 SARS-CoV-2 infection: A 6-month follow-up study. Int Forum Allergy Rhinol. 558 2021;11(8):1249-52. 559 Tan BKJ, Han R, Zhao JJ, et al. Prognosis and persistence of smell and taste 560 dysfunction in patients with covid-19: meta-analysis with parametric cure 561 modelling of recovery curves. BMJ. 2022;378:e069503. 562 Klimek L, Hagemann J, Hummel T, et al. Olfactory dysfunction is more severe in wild-type SARS-CoV-2 infection than in the Delta variant (B.1.617.2). World 563 564 Allergy Organization Journal. 2022;15(6):100653. 565 48. Chen M, Shen W, Rowan NR, et al. Elevated ACE-2 expression in the olfactory 566 neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 567 entry and replication. Eur Respir J. 2020;56(3):2001948. 568 Khan M, Yoo S-J, Clijsters M, et al. Visualizing in deceased COVID-19 patients 569 how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the 570 olfactory bulb. Cell. 2021;184(24):5932-5949.e15.

571 50. Clara B, Audrey SA, Ophélie A-G, et al. Neutrophils initiate the destruction of the olfactory epithelium during SARS-CoV-2 infection in hamsters [Internet].

607

573 Immunology; 2022 Mar [cited 2022 Jun 26]. Available from: 574 http://biorxiv.org/lookup/doi/10.1101/2022.03.15.484439 51. Khan M, Cliisters M, Choi S, et al. Anatomical barriers against SARS-CoV-2 575 576 neuroinvasion at vulnerable interfaces visualized in deceased COVID-19 577 patients. Neuron. 2022;110(23):3919-3935.e6. 578 Ho C-Y, Salimian M, Hegert J, et al. Postmortem Assessment of Olfactory Tissue 579 Degeneration and Microvasculopathy in Patients With COVID-19. JAMA Neurol. 580 2022; 581 53. Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 582 neurology: clinical, radiological and laboratory findings. Brain. 2020;143(10):3104-20. 583 584 Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes 585 in brain structure in UK Biobank, Nature, 2022:1-17. 586 55. Carfi A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 587 588 2020;324(6):603-5. 589 56. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute 590 seguelae of COVID-19. Nature. 2021;594(7862):259-64. 591 Patterson A, Hähner A, Kitzler HH, Hummel T. Are small olfactory bulbs a risk for 592 olfactory loss following an upper respiratory tract infection? Eur Arch 593 Otorhinolaryngol. 2015;272(11):3593-4. 594 595 596 **CORRESPONDING AUTHOR** 597 598 Marvin Petersen, MD 599 mar.petersen@uke.de 600 Department of Neurology 601 University Medical Center Hamburg-Eppendorf 602 Martinistraße 52, 20246 Hamburg, Germany 603 +4940-7410-59094 604 **FIGURES** 605 606 Figure 1: Exemplary 3D visualization of olfactory bulb segmentation results.

Volumetric visualization of the left and right olfactory bulb (highlighted) and

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628 629

630

631

surrounding brain areas. a) coronal, anterior-posterior; b) axial, inferior-superior; c) sagittal, right-left.

Figure 2: Association of olfactory bulb volume and olfactory function. a) Trajectory of olfactory function along timepoints. Blue dots indicate proportion of individuals with olfactory dysfunction. Gray dots show the average impairment as operationalized by the visual analogue scale. b) Group differences of olfactory bulb volume at baseline between participants with and without olfactory dysfunction with respect to different timepoints. Olfactory bulb volume at baseline was significantly lower in individuals that exhibited olfactory dysfunction during both examination timepoints but not during the acute infection. c) Association of the time interval from positive PCR to examination and olfactory bulb volume. A smaller interval was significantly associated with lower olfactory bulb volume. d) Linear associations between olfactory bulb volume and olfactometry scores. A low olfactory bulb volume at baseline was significantly associated with a lower olfactometry score at follow-up. e) Group differences of olfactory bulb volume between participants with sustained olfactory dysfunction at follow-up and those with recovered olfaction to that point. Olfactory bulb volume was significantly lower in participants with sustained olfactory dysfunction. Abbreviations:  $eta_n^2$  = partial eta squared indicating the effect size as provided by the analysis of covariance, p = p-value,  $r_{sp} = spearman$  correlation coefficient, PCR = polymerase chain reaction, T1 = at baseline, T2 = at follow-up.

## **TABLES**

#### Table 1. Characteristics of Post-SARS-CoV-2 Individuals

Demographics	
Age in years, mean [CI95] (n)	55.79 [54.83, 56.73] (224)
Female sex at birth, % (n)	44.2 (224)
Education in years, mean [CI95] (n)	15.83 [15.50, 16.16] (224)
Current smokers, % (n)	5.4 (224)
Allergic rhinitis, %	33.3 (224)

4.4 (224)	
COVID-19	
253.15 [242.00, 264.29] (223)	
663.51 [646.04, 680.98] (143)	
8.4 (224)	
67.1 (143)	
7.62 [7.06, 8.18] (95)	
21.0 (143)	
3.79 [3.12, 4.47] (29)	
17.5 (143)	
2.96 [2.07, 3.84] (24)	
10.18 [9.89, 10.48] (143)	
45.53 [43.84, 47.21] (224)	
<u>l</u>	
69.96 [66.55, 73.37] (206)	
8.51 [8.28, 8.74] (205)	
28.25 [27.42, 29.08] (206)	
28.42 [28.25, 28.60] (205)	

632

Patient Health Questionnaire 9, T1, mean [CI95] (n)	3.54 [3.05, 4.03] (218)
EQ5D, T1, mean [CI95] (n)	80.74 [78.76, 82.72] (206)

Abbreviations: CI95 = 95% confidence interval of the mean, n = number of data points, PCR = polymerase chain reaction, post-SARS-CoV-2 = individuals who have recovered from a severe acute respiratory coronavirus type 2 infection, T1 = at baseline, T2 = at follow-up.



